Ocugenix

Ocugenix is a company headquartered in the United States. Its most recent tracked round is Seed. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

Ocugenix develops disease-modifying therapies for eye diseases such as wet age-related macular degeneration, geographic atrophy, proliferative diabetic retinopathy, and dry eye by activating natural wound healing pathways to resolve inflammation, fibrosis, and abnormal vessel growth.